44Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations

EJNMMI Radiopharmacy and Chemistry

Volumn 1, Issue 1, 2016, Pages

  Domnanich, Katharina A ^a,b   Müller, Cristina ^c,d   Farkas, Renata ^c   Schmid, Raffaella M ^c   Ponsard, Bernard ^e   Schibli, Roger ^c,d   Türler, Andreas ^a,b   van der Meulen, Nicholas P ^a,c  

^a PAUL SCHERRER INSTITUTE   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c ETH Zurich   (Switzerland)

^d ETH ZURICH   (Switzerland)

^e BELGIAN NUCLEAR RESEARCH CENTRE   (Belgium)

Author keywords

44Sc; 68Ga; AR42J; DOTA NOC; DOTA RGD; Imaging; NODAGA NOC; NODAGA RGD; PET; Stability; U87MG

Indexed keywords

1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID GA 68; 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID SC 44; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; TETRAXETAN GA 68; TETRAXETAN SC 44; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RETENTION; DRUG STABILITY; DRUG STRUCTURE; DRUG UPTAKE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PANCREAS TUMOR; PET SCANNER; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY;

EID: 84994867019     PISSN: None     EISSN: 2365421X     Source Type: Journal    
DOI: 10.1186/s41181-016-0013-5     Document Type: Article

References (27)

1. Banerjee SR, Pomper MG. Clinical applications of gallium-68. Appl Radiat Isot. 2013;76:2–13. doi:10.1016/j.apradiso.2013.01.039.
2. 44Sc-labeled cetuximab Fab fragment. Bioconjug Chem. 2014;25(12):2197–204. doi:10.1021/bc500415x.
3. 68Ga-RGD positron emission tomography in pediatric cerebral infarct. Mol Imaging. 2013;12(4):213–7.
4. 3 integrin expression. Eur J Nucl Med Mol Imaging. 2008;35(8):1507–15. doi:10.1007/s00259-008-0757-6.
5. 44Sc-DOTA-puromycin. Mol Imaging Biol. 2013;15(1):79–86. doi:10.1007/s11307-012-0561-3.
6. 111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem. 2002;13(3):530–41.
7. Elander N, Jones JR, Lu SY, Stone-Elander S. Microwave-enhanced radiochemistry. Chem Soc Rev. 2000;29(4):239–49. doi:10.1039/a901713e.
8. 44Sc: an attractive isotope for peptide-based PET imaging. Mol Pharm. 2014;11(8):2954–61. doi:10.1021/mp500343j.
9. Huclier-Markai S, Sabatie A, Ribet S, Kubicek V, Paris M, Vidaud C, et al. Chemical and biological evaluation of scandium(III)-polyaminopolycarboxylate complexes as potential PET agents and radiopharmaceuticals. Radiochim Acta. 2011;99:653–62.
10. 68Ga-NOTA-RGD, a positron emission tomography agent for angiogenesis imaging. Cancer Biother Radiopharm. 2012;27(1):65–71. doi:10.1089/cbr.2011.1061.
11. 3 integrin expression. Eur J Nucl Med Mol Imaging. 2011;38(7):1303–12. doi:10.1007/s00259-011-1778-0.
12. 44Sc a potential radionuclide for PET? Appl Radiat Isot. 2012;70(12):2669–76. doi:10.1016/j.apradiso.2012.08.004.
13. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17(1):R53–73. doi:10.1677/ERC-09-0078.
14. Majkowska-Pilip A, Bilewicz A. Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals. J Inorg Biochem. 2011;105(2):313–20. doi:10.1016/j.jinorgbio.2010.11.003.
15. 44Sc-DOTATOC. Eur J Nucl Med Mol Imaging. 2011;38:S158-S.
16. 44Sc-DOTA-folate conjugate. J Nucl Med. 2013;54(12):2168–74. doi:10.2967/jnumed.113.123810.
17. 47Sc for radionuclide tumor therapy in mice. J Nucl Med. 2014;55(10):1658–64. doi:10.2967/jnumed.114.141614.
18. Notni J, Pohle K, Wester HJ. Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET. EJNMMI Res. 2012;2(1):28. doi:10.1186/2191-219X-2-28.
19. 68Ga-labeling of DOTATATE. Appl Radiat Isot. 2013;82:232–8. doi:10.1016/j.apradiso.2013.08.010.
20. 18F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol. 2012;39(6):777–84. doi:10.1016/j.nucmedbio.2012.02.006.
21. Port M, Idee JM, Medina C, Robic C, Sabatou M, Corot C. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals. 2008;21(4):469–90. doi:10.1007/s10534-008-9135-x.
22. 44Sc. Appl Radiat Isot. 2012;70(6):974–9. doi:10.1016/j.apradiso.2012.03.005.
23. 44Sc generator system. Curr Radiopharm. 2012;5(3):187–201. doi:CRP-EPUB-20120529-10.
24. 68Ga generator eluates? ChemMedChem. 2013;8(1):95–103. doi:10.1002/cmdc.201200471.
25. 44Sc: From bench to bedside. Nucl Med Biol. 2015;42(9):745–51. doi:10.1016/j.nucmedbio.2015.05.005.
26. Viola-Villegas N, Doyle R. The coordination chemistry of 1,4,7,10-tetraazacyclododecane-N, N’, N”, N‴-tetraacetic acid (H4DOTA): Structural overview and analyses on structure-stability relationships. Coordin Chem Rev. 2009;253:1906–25.
27. 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2014;41(8):1534–43. doi:10.1007/s00259-014-2744-4.